SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as an UBS upgrade sparked bullish sentiment, with the community eyeing a potential short squeeze and significant gains. Traders are closely watching NIO Day and ES8 deliveries, drawing comparisons to other EV manufacturers like Tesla. The stock is facing resistance, but many believe it has the potential to reach much higher prices.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending due to speculation around potential government contracts and recent congressional stock disclosures, fueling retail trader buzz. The community is actively discussing the possibility of a short squeeze and anticipating further gains, with some drawing comparisons to Palantir's growth trajectory. High options volume and increasing interest from institutional investors are adding to the positive sentiment.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

Turbo Energy (TURB) is trending due to a significant $53 million contract to deploy solar storage projects, sparking excitement about the company's growth potential in the energy sector. Community discussions revolve around the stock's volatile price action, potential short squeeze opportunities, and comparisons to other high-flying stocks. Some traders are also noting its low float, which may contribute to price swings.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the company received UK regulatory approval for its acquisition of Oxford Ionics, potentially accelerating its technology roadmap; the community is actively discussing the deal's implications and future catalysts such as the Quantum World Congress. Bullish sentiment is fueled by analyst upgrades, increased price targets, and perceived momentum in the quantum computing sector, while bears question the valuation and long-term profitability.

Lazydays Holdings, Inc. retails recreational vehicles, motorcycles, jet skis and related accessories. The company operates recreation vehicle dealerships, generating revenue by providing RV owners a full spectrum of products: RV sales, RV services, financing and insurance products, RV parts and accessories, RV rentals, third-party protection plans, and RV camping. Lazydays Holdings was founded in 1976 and is headquartered in Tampa, FL.

Lazydays Holdings Inc

Lazydays Holdings ($GORV) is trending due to a recent acquisition announcement and a letter of intent with Campers Inn, including consideration for furniture and equipment. The community is actively discussing the potential impact of this acquisition, with some speculating about a pump and dump, while others are encouraged by the company's book value. Discussions also include the possibility of future offerings and price targets.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin ($APP) is trending as investors speculate on potential catalysts, including S&P 500 inclusion and possible involvement in a TikTok deal. The community is actively discussing the stock's strong upward momentum and potential overvaluation, with some anticipating a significant pullback while others remain bullish on its international expansion and growth prospects. Traders are also noting the stock's high volatility and potential for short squeezes.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to its low float and potential for a short squeeze, mirroring the recent movements of other low-float stocks. The community is actively discussing its high trading volume relative to its float, with some suggesting it could reach new highs. Several users are pointing to the company's fundamentals, such as cash position and lack of debt, as reasons for potential growth.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending as community members highlight its strength within the defense sector and potential for further gains, with some eyeing triple-digit prices. A catalyst appears to be related to upcoming events and potential news, leading to discussions around its involvement in key defense programs. Investors are actively discussing its valuation, growth prospects, and potential contracts within the broader context of increasing defense spending.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards HPC/AI, drawing comparisons to other miners already in the space like $IREN and $CIFR. Community members are weighing the company's existing Bitcoin mining operations against opportunities in the AI sector, while also noting a high short interest and potential for a short squeeze. Some traders are monitoring borrowing fees and levels, while others discuss technical indicators and potential price movements related to broader market trends.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending amid discussions around recent executive stock sales, a completed acquisition, and revised financial guidance, leading to mixed sentiment. While some investors express frustration over the stock's volatile behavior and perceived mismanagement, others remain bullish, pointing to the company's long-term potential and strategic moves. Community talking points include potential catalysts, market manipulation, and the impact of institutional ownership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Invesco RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?

Should Invesco RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?

Tilray Brands, Inc. faces a regulatory reckoning: regain Nasdaq’s minimum bid price requirements soon or possibly get delisted from the exchange.&nbsp;The retail trading community on Stocktwits believes the cannabis and beer company will soon overcome this hurdle.Leamington, Canada-based Tilray received a non-compliance notice from Nasdaq on Tuesday after its stock failed to maintain the exchange’s $1 minimum closing bid price requirement for 30 consecutive business days.Shares of Tilray have lost more than half their value this year, as cannabis-linked stocks continue to struggle amid stalled federal legalization efforts.The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.If the company fails, it may transfer to the Nasdaq Capital Market for another 180-day extension — provided it meets other listing requirements and notifies Nasdaq of its plan to fix the issue, possibly through a reverse stock split.&nbsp;If Nasdaq still determines the company cannot regain compliance, its stock will face delisting.On Stocktwits, sentiment for Tilray ended on a slightly higher ‘bullish’ level on Wednesday amid a 45% jump in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/TLRY_sentiment_and_message_volume_as_of_Macrh_26_png_785b929906.webp" alt="TLRY sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>TLRY sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One user expressed hopes of Nasdaq being lenient with its process and said there were “zero” delisting fears because, with the extension, Tilray has until April 2026 to regain compliance.<stembedurl>https://stocktwits.com/Finance88/message/609341203</stembedurl>Another user said the company is “vertically scaled to be dominant from flower to drinks to pharma,” pointing to its products being available on the multinational supermarket chain Whole Foods, which is owned by Amazon.com.<stembedurl>https://stocktwits.com/Heb1972/message/609362664</stembedurl>Several retail investors on Stocktwits hope Tilray does not resort to a reverse stock split.<stembedurl>https://stocktwits.com/Rs1015/message/609258289</stembedurl>In January, Tilray’s stock was dealt a blow after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tlry-stock-slides-after-q2-2025-results/chGWAd2RZD">reported</a> disappointing quarterly results and projected a $20 million revenue blow for 2025 from cutting back on certain alcohol beverage brands.Meanwhile, the company said Wednesday that the Massachusetts Superior Court dismissed a lawsuit filed by a shareholder against the company and its subsidiary Hexo.The plaintiff claimed Tilray failed to inform shareholders about Hexo’s corporate actions in late 2022 and its 2023 acquisition, allegedly causing financial losses. He sought nearly $8 million in damages.&nbsp;According to Koyfin data, short interest on Tilray has shot up from 12.7% at the start of the year to 17.3% as of the last week.The stock trades at a significant 180% discount to Wall Street’s average price target of $1.83. Out of 13 analysts covering it, nine rate it ‘hold’ and four ‘buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of a Canadian pharmaceutical and cannabis company, Tilray, is seen on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Tilray Retail Bulls See Nasdaq Compliance On The Horizon, Shareholder Lawsuit Victory Adds Cheer

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.

Equity

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.


Shares of Tilray Brands tumbled over 12% on Thursday, hitting their lowest point since Dec. 20, as the cannabis and beer company reported disappointing fiscal second-quarter (Q2) results and projected a $20 million revenue blow for 2025.The company posted a Q2 net loss of $85.3 million, nearly doubling its year-ago loss of $46.2 million.&nbsp;Cannabis net revenue fell slightly to $66 million from $67 million in the prior year.&nbsp;While overall Q2 revenue rose 8.8% year-over-year to $211 million, it missed Wall Street’s estimate of $216.33 million.Tilray also launched “Project 420,” a $25 million initiative to streamline its beverage business.&nbsp;The plan involves cutting back on certain alcohol beverage brands,&nbsp;which will contribute to the $20 million anticipated revenue impact for fiscal 2025.&nbsp;The company cited prioritizing key products and discontinuing underperforming stock keeping units (SKUs) as reasons for the dip.&nbsp;For the six months ended Nov. 30, 2024, the company reported a $6.0 million reduction in net sales, driven by the prioritization of certain products in key markets.&nbsp;An additional $2.0 million decline resulted from the decision to discontinue specific SKUs due to market conditions, Tilray said.However,&nbsp;the firm expects the move to be offset by innovation in new beverage categories and brand extensions over the next 18 months.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TLRY_sentiment_and_message_volume_Jan_10_premarket_d6cc8d488d.png" alt="TLRY sentiment and message volume Jan 10 premarket.png" width="1318" height="324"><figcaption>TLRY sentiment and message volume Jan 10 as of 11 am ET | source: Stocktwits</figcaption></figure>Despite the underwhelming financial performance, retail investors on Stocktwits remained surprisingly bullish.&nbsp;Many speculated on the possibility of a reverse stock split and expressed optimism about management’s potential for a turnaround.&nbsp;<stembedurl>https://stocktwits.com/PerCentInvestments/message/599550073</stembedurl><stembedurl>https://stocktwits.com/PerCentInvestments/message/599550073</stembedurl><stembedurl>https://stocktwits.com/Finer1m2/message/599547388</stembedurl><stembedurl>https://stocktwits.com/Big_Fish_76/message/599462909</stembedurl>There was also some solace in Tilray breaking even on an adjusted basis, outperforming analysts’ expectations of a $0.03 per share loss.<a href="https://stocktwits.com/symbol/TLRY">Tilray's stock</a> lost 34% in 2024.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tilray Stock Dips To 4-Week Low On $20M Revenue Blow Projection For 2025, But Retail’s Still Riding High

Tilray launched “Project 420,” a $25 million initiative to streamline its beverage business that involves cutting back on certain alcohol brands.

Shares of Sangamo Therapeutics ($SGMO) came under pressure in Monday’s after-hours trading session after the termination of the company’s collaboration agreement with Pfizer Inc. ($PFE) related to its hemophilia A gene therapy product, spiking retail chatter.Sangamo said it will gain development and commercialization rights to “giroctocogene fitelparvovec,” an investigational gene therapy product candidate for treating adults with ‘moderately severe’ to ‘severe hemophilia’ A that it co-developed with and licensed to Pfizer.Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner, the company said in a statement.Following the announcement, retail sentiment on Stocktwits turned ‘neutral’ from ‘bearish’ a day ago. Message volumes climbed to ‘extremely high’ zone from ‘low’ in the same period.<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_31_at_3_06_34_PM_7cc280f2ef.png" alt="Screenshot 2024-12-31 at 3.06.34 PM.png" width="1256" height="302"><figcaption>SGMO sentiment meter and message volumes on Dec 31 as of 4:30 am ET</figcaption></figure><stembedurl>https://stocktwits.com/johnnydequino/message/598318745</stembedurl><stembedurl>https://stocktwits.com/stephanjk59/message/598298795</stembedurl>Meanwhile, Barclays kept an ‘Overweight’ rating with a $9 price target, saying that while Pfizer's (PFE) decision came as a big surprise given the prior comments of a Biologics License Application filing in early FY25, the stock move is "overdone," The Fly.com reported. A "limited valuation" was assigned to the HemoA program, said the report, citing the analyst.Sangamo is due to report quarterly earnings in March. Wall Street expects the company to post loss per share of around $0.09 in Q4 on estimated revenue of about $8.8 million, according to Stocktwits data.Sangamo stock is up 318% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious

Sangamo intends to explore all options to advance the program,

Shares of CommScope Holding Company Inc. ($COMM) rose 0.60% during Tuesday’s after-hours trading session following its announcement of a debt refinancing transaction to strengthen its capital structure, lifting retail sentiment.<a href="https://stocktwits.com/symbol/COMM">CommScope</a>, a provider of network connectivity solutions, entered the refinancing deal with its “first-lien” secured lenders, the company said. The debt refinancing will enable the company to address its upcoming 2025 and 2026 debt maturities and position the company for future success, it added.The first-lien lenders include funds managed by Apollo and Monarch Alternative Capital. The debt includes a new $3.15 billion first-lien term loan, maturing in 2029, and $1 billion in first-lien notes, maturing in 2031.Following the news, retail sentiment on Stocktwits was ‘extremely bullish’. Message volumes were &nbsp;at ‘extremely high’ levels.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_18_at_9_23_23_AM_ee9cb55050.png" alt="Screenshot 2024-12-18 at 9.23.23 AM.png"><stembedurl>https://stocktwits.com/varooommm/message/596894271</stembedurl><stembedurl>https://stocktwits.com/Curioustock/message/596886573</stembedurl><stembedurl>https://stocktwits.com/StockAutoPro/message/596471118</stembedurl>“This transaction is a pivotal step forward in our ongoing process to position CommScope for long-term growth,” Chuck Treadway, president and CEO of CommScope, said in a statement. &nbsp;“By successfully addressing our near-term maturities and greatly improving our pro forma leverage ratio, we move forward with the flexibility to focus on our core businesses and invest in the technology, products, and personnel to better deliver for our customers, and capitalize as the telecom industry recovers in the coming quarters."For its most recent quarter, the company’s non-GAAP adjusted net loss per diluted share narrowed to $0.05 from $0.12.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CommScope Holding Stock Rises On Strategic Refinancing: Retail’s Optimistic

The debt includes a new $3.15 billion first-lien term loan, maturing in 2029, and $1 billion in first-lien notes, maturing in 2031.

Shares of digital insurer Lemonade, Inc. (<a class="mention" data-mention="$LMND" data-symbol-id="LMND" href="https://stocktwits.com/symbol/LMND" target="_blank">$LMND</a>) surged over 6% in pre-market trading Wednesday, positioning the stock to hit near three-year highs if the momentum holds.&nbsp;The rally follows an upgrade from Morgan Stanley, which raised its rating on LMND to ‘Equal Weight’ from ‘Underweight’ and boosted the price target to $42 from $23, citing optimism about the company’s long-term growth potential after its recent investor day event.Morgan Stanley said Lemonade has "charted an ambitious goal" to grow its gross earned premiums (GEP) from $1 billion to $10 billion over the coming years.&nbsp;The brokerage praised the company’s “differentiated” AI-driven technology and its roadmap to achieve net profit positivity by the end of 2027 — well ahead of consensus estimates.An illustrative slide from Lemonade’s investor presentation reportedly suggested a potential valuation of $90 per share, assuming a 30% compound annual growth rate in GEP and a 12% adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) ratio over seven years.&nbsp;That projection implies a 125% upside from the previous session’s close of just over $40.<figure class="image"><a href="https://stocktwits.com/symbol/LMND"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_20_at_6_15_37_PM_19d0e9dfa0.png" alt="Screenshot 2024-11-20 at 6.15.37 PM.png" width="1318" height="318"></a><figcaption>LMND sentiment and message volume on Nov 20 as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment mirrored the market’s enthusiasm, with the score flipping into the ‘extremely bullish’ zone pre-market.&nbsp;Discussions about Lemonade spiked significantly, reflecting renewed optimism around the stock’s future prospects.<stembedurl>https://stocktwits.com/OMillionaires/message/593297569</stembedurl>&nbsp;<stembedurl>https://stocktwits.com/KashChick/message/593297772</stembedurl>&nbsp;Last month, Lemonade reported third-quarter revenue of $136.6 million, up 19% year-over-year, driven by increases in premiums and investment income.&nbsp;While its adjusted EBITDA loss widened to $49 million from $40.2 million a year earlier due to growth-related spending, the company’s per-share loss of $0.95 came in better than the expected $1.00.LMND shares have gained over 135% year-to-date, outperforming broader market indices as investors increasingly bet on the company’s disruptive approach to the insurance industry.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/target-corporation-stock-plummets-premarket-after-q3-earnings-miss/cJ460tORXb">Target Stock Plummets Pre-Market After Q3 Earnings Miss, Lowered Guidance: Retail’s Worried About Tariff Impact</a>

Morgan Stanley said Lemonade has "charted an ambitious goal" to grow its gross earned premiums (GEP) from $1 billion to $10 billion over the coming years. 

Lemonade Stock Jumps Pre-Market As Morgan Stanley Upgrades On Growth Optimism: Retail Rides Along 

The brokerage praised the company’s “differentiated” AI-driven technology and its roadmap to achieve net profit positivity by the end of 2027.

Shares of Danimer Scientific ($DNMR) were down 12.76% as of 12:28 p.m. ET on Tuesday following the bioplastics maker’s third-quarter earnings, pushing down retail sentiment.Danimer is involved in the production of biodegradable plastic used by many consumer brands intent on replacing petroleum-based plastics. Among its PHA customers is Starbucks, which uses this material in its straws, and Mars Wrigley.Danimer’s revenues fell to $8.6 million in the third quarter from $10.9 million in the same period last year, roughly in line with Wall Street estimates of $8.58. While earnings per share (EPS) stood at -$7.20 compared to -$7.98 expected by Wall Street analysts.Its revenue specifically from PHA products fell to $6.6 million, reducing by $1.8 million from the year-ago period. It cited “reapportionment of Starbucks’ straw business” that led to significant disruptions in its order patterns. Richard N. Altice, Interim CEO of Danimer, said the company is focused on preserving liquidity and looking at a “variety of transactions” to strengthen its capital structure. Retail sentiment on the stock fell to ‘neutral’ (51/100) from ‘bullish’ (68/100) a day ago, while message volumes rose to ‘high’ (67/100) from ‘normal (48/100).<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_19_at_11_01_49_PM_a96736efff.png" alt="Screenshot 2024-11-19 at 11.01.49 PM.png" width="1304" height="290"><figcaption>DNMR sentiment meter and message volume on Nov 19 as of 12:31 pm| Source" Stocktwits</figcaption></figure>“We believe these headwinds are behind us, and it is important to reiterate that we have retained 100% of this business. We remain on track to continue to grow our PHA business into fiscal 2025,” Altice said in the statement.Altice noted the company is confident about the soft launch of 100% compostable Skittles packaging, which was featured at a Seattle Seahawks NFL game in October 2024. That packaging is made with its Nodax PHA resin.&nbsp; “While we remain focused on executing these commercial opportunities, we are mindful of managing our indebtedness levels and near-term constraints on liquidity as we enter our anticipated significant commercial ramp over the next twelve months,” Altice added. In May, Danimer received a non-compliance notice from the NYSE for maintaining an average closing price of not less than $1.00 per share over a period of thirty consecutive trading days. The notice did not result in the immediate delisting of the company's common stock from the NYSE.Danimer stock is down 83.17% year-to-date.&nbsp;For updates and corrections, email newsroom@stocktwits.com. &nbsp;

Danimer is involved in the production of biodegradable plastics| Image source: Pixabay

Danimer Scientific Stock Slips After Q3 Earnings; Retail Sentiment Wanes

Richard N. Altice, Interim CEO of Danimer, said the company is focused on preserving liquidity and looking at a “variety of transactions” to strengthen its capital structure. 

Invesco Capital Management LLC - Invesco RAFI US 1500 Small-Mid ETF

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Current Price	$45.24
Prev Close	$45.41
Open	$45.18
Dividend Yield	N/A
50-Day Moving Average	$43.01
Beta	N/A
Avg. Volume	82,282.76
PE Ratio	N/A

52-Week High	$45.83
52-Week Low	$32.53
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PRFZ
Invesco FTSE RAFI US 1500 Small-Mid ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PRFZ News

PRFZ Invesco FTSE RAFI US 1500 Small-Mid ETF